Concerns rise over Walgreen's Medco contracts
The drugstore chain's March sales declined without Express Scripts.
Now with Medco Health Solutions (MHS) folding into Express Scripts, there are obvious concerns about the future of Walgreen's business with Medco, although Walgreen says it hopes to honor its existing contracts. Medco represented around 125 million prescriptions for Walgreen in 2011. There are also expectations that Walgreen may try to renegotiate a deal with Express Scripts.
Walgreen competes with CVS Caremark (CVS) and Rite Aid (RAD).
March metrics dip
Walgreen's March sales decreased by 4.3% compared to March 2011 due to reduced pharmacy sales as it's no longer part of Express Scripts network. As a result, prescriptions filled at its comparable stores declined by 11.4%, leading to 11% lower pharmacy sales. Comparable store pharmacy sales also were negatively impacted by 2.5 percentage points due to generic drug introductions and by 1 percentage point due to lower incidence of cough, cold and flu.
Concerns over Medco contracts
Walgreen has walked out of Express Scripts network last year over the reimbursement rate dispute. Now, Express's acquisition of Medco has raised concerns over the future of Walgreen-Medco contracts. Walgreen says it hopes to maintain its contracts with Medco, unless the new company takes "an extraordinary action" to terminate the existing contracts or significantly modify the terms of the agreements. Meanwhile, there are also rumors that Walgreen may try to enter into a fresh deal with Express Scripts.
We currently value Walgreen with a $35 Trefis price estimate of its stock, which is almost in-line with the current market price.
MORE ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
This young tech company has a can't-miss concept, but hasn't yet generated real sales. Should you see its recent slump as a buying opportunity, or reason to stay away?
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.